



12th IELSG MEETING PROGRAM TORONTO APRIL 24-25, 2009

FRIDAY APRIL 24

<p><i>M Gospodarowicz (Toronto, Canada) E Zucca (Bellinzona, Switzerland)</i></p> <p>Opening remarks</p>	9.15 - 9.30 am
<p><i>AJ Ferreri and M Ponzoni (Milan, Italy)</i></p> <p>Primary Lymphomas of the ocular adnexae</p> <ul style="list-style-type: none"> • Chlamydothylae and lymphomas: a dangerous liaison (<i>M Ponzoni</i>) • <i>C. psittaci</i> or other bugs? The role of antibiotics in OAL (<i>AJ Ferreri and M Ponzoni</i>) • Update of the IELSG-27 study (<i>AJ Ferreri</i>) 	9.30 - 10.20 am
<p><i>A Conconi (Novara, Italy)</i></p> <p>Systemic treatment of MALT lymphomas 1</p> <ul style="list-style-type: none"> • Final results of the IELSG-25 study of Bortezomib in MALT lymphoma • Proposal of a phase II study of Everolimus (RAD001) 	10.20 - 10.40 am
<p>coffee break</p>	10.40 - 11.00 am
<p><i>M Ponzoni (Milan, Italy)</i></p> <p>Intravascular large B cell lymphoma</p> <ul style="list-style-type: none"> • Intravascular large B cell lymphoma: how many disease entities? Achievements from IELSG studies and proposals for future collaborations (<i>M Ponzoni</i>) 	11.00 - 11.30 am
<p><i>AJ Ferreri (Milan, Italy) G Illerhaus (Freiburg, Germany)</i></p> <p>Primary Lymphomas of the CNS.</p> <ul style="list-style-type: none"> • Primary CNS lymphoma: open questions and ongoing clinical studies (<i>AJ Ferreri</i>) • IELSG-20 final results (<i>AJ Ferreri</i>) • Which role for ASCT in CNS lymphoma? (<i>G Illerhaus</i>) • The Next IELSG-32 study (<i>AJ Ferreri and G Illerhaus</i>) 	11.30 - 12.10 am
<p><i>G Ryan (Melbourne, Australia) G Martinelli (Milan, Italy)</i></p> <p>The breast lymphoma studies</p> <ul style="list-style-type: none"> • Summary of previous achievements in aggressive ... (<i>G Ryan</i>) • ... and indolent breast cancer (<i>G Martinelli</i>) • IELSG-33 Breast Lymphoma (<i>G Ryan</i>) 	12.10 - 12.40 pm
<p>lunch</p>	1.00 - 2.00 pm

FRIDAY APRIL 24

<i>PWM Johnson (Southampton, UK) and M Martelli (Rome, Italy)</i> Primary Mediastinal B-Cell Lymphoma: where we are and where we may go	2.00 - 3.00 pm
<ul style="list-style-type: none"> • PMLCL a specific entity needing specific clinical trials? (<i>PWM Johnson</i>) • PET evaluation in large cell lymphoma: open problems (<i>PWM Johnson</i>) • PMLCL outcome in the MinT study (<i>M Martelli</i>) • Update of the IELSG-26 study (<i>M Martelli</i>) • Discussion of future programs (<i>PWM Johnson and M Martelli</i>) 	
Other IELSG studies update	3.00 - 4.00 pm
<ul style="list-style-type: none"> • IELSG-30 Testis lymphoma (<i>E Zucca</i>) • IELSG-11 Cutaneous B-cell lymphoma (<i>M Mian, Bolzano, Italy</i>) • IELSG-23 Head and neck lymphoma (<i>M Mian</i>) • IELSG-28 on lung lymphoma (<i>G Martinelli</i>) • IELSG-29 on bone marrow lymphoma (<i>M Rozman, Barcelona, Spain</i>) • IELSG-31 on follicular lymphoma (<i>E Zucca</i>) 	
<i>PWM Johnson</i> A new study proposal for a phase II evaluation of PSCT in enteropathy-type T-cell lymphoma	4.00 - 4.30 am
coffee break	4.30 - 5.00 pm
<i>L Pasqualucci (New York, USA)</i> FIRST EDUCATIONAL LECTURE Molecular pathogenesis of diffuse large B-cell lymphomas	5.00 - 6.00 pm
dinner	7.45 pm

SATURDAY APRIL 25

<i>The Board of Directors</i> Board of Directors Breakfast meeting	8.00 - 9.00 am
<i>R Gascoyne (Vancouver, Canada)</i> SECOND EDUCATIONAL LECTURE Hodgkin's lymphoma: understanding the biology and relationship to survival	9.00 - 10.00 am
coffee break	10.00 - 10.30 am
<i>E Zucca</i> Systemic treatment of MALT lymphomas 2	10.30 - 11.00 am
<ul style="list-style-type: none"> • Update of the IELSG-19 study with final analysis of the 2-arm part of the trial and interim analysis of the 3-arm part and discussion of future programs • Which design for a next phase III study? 	
<i>M Gospodarowicz and E Zucca</i> General Assembly, discussion of administrative issues and conclusive remarks	11.00 - 12.00 am
PRINCESS MARGARET HOSPITAL TOUR	12.30 - 1.30 pm